Xtandi Share May Increase as Second-Line Drug in US, Ranks Top as Third-Line Drug: Kantar Health

US-based Kantar Health consultants said that the share of Astellas Pharma’s prostate cancer treatment Xtandi (enzalutamide) as a second-line therapy may increase in the US market. Xtandi, launched by Astellas in the US in September, became a top third-line treatment...read more